MB

Megan Baldwin

Dr Baldwin is currently over-seeing the expansion of the company's management team in the U.S. and preparing for commercialization of OPT-302. Dr Baldwin is a biotechnology executive, having over 20 years of experience working on therapeutic drug development programs for cancer and ophthalmic indications. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair. Dr Baldwin is considered an independent Director.

Holdings

Company
Last Notice
Direct Shares
Indirect Shares
Options
Convertibles
30/06/240N/A50,000N/A
28/09/23987,7232,851,6753,000,000N/A

Transactions

Company
Date
Type
Amount
Price
Value
Notes
09/04/24
Cancelled
400,000$0.084$33,600As advised by the company
01/03/24
Sell
987,723$0.550$543,247As advised by the company
01/03/24
Sell
3,012,277$0.550$1,656,752As advised by the company
21/12/23
Issued
3,000,000$0.470$1,410,000Issue of options
10/11/23
Cancelled
100,000$0.225$22,500As advised by the company